As a model capsule-based DPIs, Spiriva® Handihaler® was purchased from Boehringer Ingelheim Japan Ltd. Spiriva® Handihaler® is a typical capsule-based DPIs, used for the treatment of COPD and for reducing COPD exacerbations. A dry powder in Spiriva® inhalation capsules containing tiotropium bromide (TIO) as the main component was used as a model drug. The capsule contained 5.5 mg of a powder formulation consisting of 18 µg micronized tiotropium (as bromide hydrate, 22.5 µg) with coarse lactose monohydrate (24 (link)). The Handihaler® (Boehringer Ingelheim Japan Ltd.) was used as a model high resistance device for capsule-based DPIs (device specific resistance 3.03 Pa* min2/l2) (25 (link)). Size 3 capsules with different compositions were supplied by Qualicaps, Co., Ltd. (G-Cap, gelatin capsule; PEG/G-Cap, gelatin capsule containing 5% PEG4000 as plasticizer; and HPMC-Cap, HPMC capsule). PEG/G-Cap is a gelatin capsule that is resistant to cracking due to the presence of PEG. HPMC-Cap is resistant to cracking under dry conditions and may be filled with highly hygroscopic drugs. Each capsule was stored at 15-25˚C and under 40-50% relative humidity (RH) in a glass desiccator. The characteristics of each capsule are presented in Table I . All other reagents and solvents were of analytical or HPLC grade.
Spiriva handihaler
Manufactured by Boehringer Ingelheim
Sourced in Japan
Spiriva® Handihaler is a medical device used for the administration of the medication tiotropium bromide. It is a handheld inhalation device designed to deliver the medication directly to the lungs.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using spiriva handihaler
1
Evaluating Capsule-Based Dry Powder Inhalers
2
Randomized Crossover Study of Inhaled COPD Therapies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We carried out a randomized, open-label, cross-over study (Fig. 1 ). Previously prescribed LAMA were stopped at the screening visit. After a 1- to 2-week period on ICS/LABA, patients were randomized to either ACL (Eklira Genuair, Astra Zeneca, Luton, UK) 322 µg bid or TIO (Spiriva HandiHaler, Boehringer, Bracknell, UK) 18 µg bid. Following the run-in period, at visit 1, baseline measurements were recorded. After 2–3 weeks on the study inhaler, participants returned to the department for visit 2. All measurements were taken at trough (i.e., 12 h post dose for ACL and ICS/LABA and 24 h post dose for TIO). Participants attended the department the same time during each study visit. After the first treatment period, participants entered a wash-out period of 1–2 weeks. The same process was repeated with the other study inhaler after cross-over.![]()
After a 1- to 2-week run-in, patients received either tiotropium 18 µg od or aclidinium 322 µg bid for 2–3 weeks each with a 1- to 2-week wash-out in between. Baseline values were measured at Visit 1/3 and after chronic dosing at Visit 2/4
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!